Synergistic cytotoxic effects of an extremely low-frequency electromagnetic field with doxorubicin on MCF-7 cell line.

Abstract

Breast cancer is one of the leading causes of cancer deaths in women worldwide. Magnetic fields have shown anti-tumor effects in vitro and in vivo as a non-invasive therapy method that can affect cellular metabolism remotely. Doxorubicin (DOX) is one of the most commonly used drugs for treating breast cancer patients. It can be assumed that combining chemotherapy and magnetotherapy is one of the most effective treatments for breast cancer. This study aimed to investigate the potential cytotoxic effect of DOX at low concentrations in combination with extremely low-frequency electromagnetic fields (ELF-EMF; 50 Hz; 20 mT). The breast cancer cell line MCF-7 was examined for oxidative stress, cell cycle, and apoptosis. MCF-7 cells were treated with various concentrations of DOX as an apoptosis-inducing agent and ELF-EMF. Cytotoxicity was examined using the MTT colorimetric assay at 12, 24, and 48 h. Consequently, concentration- and time-dependent cytotoxicity was observed in MCF-7 cells for DOX within 24 h. The MTT assay results used showed that a 2 μM concentration of DOX reduced cell viability to 50% compared with control, and as well, the combination of ELF-EMF and DOX reduced cell viability to 50% compared with control at > 0.25 μM doses for 24 h. In MCF-7 cells, combining 0.25 μM DOX with ELF-EMF resulted in increased ROS levels and DOX-induced apoptosis. Flow cytometry analysis, on the other hand, revealed enhanced arrest of MCF-7 cells in the G0-G1 phase of the cell cycle, as well as inducing apoptotic cell death in MCF-7 cells, implying that the synergistic effects of 0.25 μM DOX and ELF-EMF may represent a novel and effective agent against breast cancer.

• Authors: Shahin Ramazi, Mani Salimian, Abdollah Allahverdi, Shahla Kianamiri, Parviz Abdolmaleki
• Journal: Scientific reports (Sci Rep) Vol. 13 Issue 1 Pg. 8844 (05 31 2023) ISSN: 2045-2322 [Electronic] England
• PMID: 37258563 (Publication Type: Journal Article)
• Copyright: © 2023. The Author(s).

Chemical References

• Doxorubicin
• Antineoplastic Agents

Topics

• Humans
• Female
• MCF-7 Cells
• Electromagnetic Fields
• Doxorubicin (pharmacology, therapeutic use)
• Antineoplastic Agents (pharmacology)
• Breast Neoplasms (pathology)
• Apoptosis